OnCo

Appendiceal cancer and pseudomyxoma peritonei: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Advanced, first line1
Other settings1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalised LAMN / adenocarcinomaAppendicectomy (LAMN without perforation) or right hemicolectomy (adenocarcinoma, goblet cell); adjuvant chemotherapy for node-positive adenocarcinoma by colorectal analogy.82

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersHigh-grade or unresectable peritoneal diseaseFOLFOX/CAPOX ± bevacizumab; systemic chemotherapy has no proven benefit in low-grade disease (randomised 2024).98

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersPseudomyxoma peritonei / peritoneal diseaseCytoreductive surgery with HIPEC at a peritoneal-surface-malignancy centre; repeat CRS for recurrence when feasible.60

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.